Chantal Mathieu, Julie Wych, A Emile J Hendriks, Lisa Van Ryckeghem, Timothy Tree, Piotr Chmura, Christopher Möller, Kristina Casteels, Thomas Danne, Felix Reschke, Darja Šmigoc Schweiger, Tadej Battelino, Jesper Johannesen, Birgit Rami-Merhar, Thomas Pieber, Christophe De Block, Mark Evans, Robert Hilbrands, Emanuele Bosi, Ruben H Willemsen, Supriyo Basu, Mari-Anne Pulkkinen, Mikael Knip, Miriam Cnop, Almut Nitsche, Anke M Schulte, Elisabeth Niemöller, Mark Peakman, Charlotte Wilhelm-Benartzi, David Gillespie, Lut Overbergh, Adrian P Mander, M Loredana Marcovecchio; INNODIA. Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. The Lancet 2025. Online ahead of print.